C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/28 (2006.01) A61K 39/12 (2006.01) A61K 39/395 (2006.01) C07K 14/025 (2006.01)
Patent
CA 2480162
Disclosed is a method and composition for treating tumors or infectious diseases, wherein the composition comprises an agonistic anti-CD40 antibody or a fragment thereof, and/or an agonistic anti-4-1BB antibody or a fragment thereof. The agonistic antibody molecules include fragments like Fab, (Fab')2 and Fv. The methods and compositions may further comprise polypeptides or mucleic acid sequences having or encoding a class 1 MHC or class II MHC- restricted T cell epitope.
L'invention concerne une méthode et une composition qui permettent de traiter des tumeurs ou des maladies infectieuses, la composition comprenant un anticorps agonistique anti-CD40 ou une fraction de celui-ci et/ou un anticorps agonistique anti-4-1BB ou une fraction de celui-ci. Les molécules de l'anticorps agonistique contiennent des fractions tels que Fab, (Fab')¿2? et F¿v?. La méthode et les compositions selon l'invention peuvent également comprendre des polypeptides ou des séquences d'acide nucléique comprenant ou codant un épitope de lymphocyte T restreint par le CMH de classe I par le CMH de classe II.
Diehl Linda
Melief Cornelis J. M.
Offringa Rienk
Toes Rene
Van Mierlo Geertje
Leiden University Medical Center
Ridout & Maybee Llp
LandOfFree
Induction of anti-tumor ctl immunity through in vivo... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Induction of anti-tumor ctl immunity through in vivo..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Induction of anti-tumor ctl immunity through in vivo... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1687809